← United States · Coverage record
US · SEC FORM 4
Nasus Pharma Ltd
NSRX · NYSE · CIK 0002029039 · Healthcare · Drug Manufacturers—General
INSIDER SIGNAL
1 buyers · 2 purchase transaction lines · $31.2K gross purchase
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
What is holding the score back?
- ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
- ⚠ Purchase size is modest relative to the model scale
- ⚠ Role scores low · most senior buyer: Chief Executive Officer (CEO, chair and 10% owners score lowest)
- ⚠ Purchase activity is becoming less recent
Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.
US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth & concentration
Roles in the peak window: Chief Executive Officer. Concentration uses priced qualifying P lines only and does not change the saved score.
SIGNAL HISTORY
Latest recorded score
- 35.1
- 35.1
- 35.0
- 35.0
- 34.9
Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- +4.8%
- 3M
- +14.0%
- 6M
- +59.5%
- 12M
- -51.7%
Volatility & liquidity
- Volatility
- 96.3%
- Beta
- —
- Avg daily value
- USD 56,010
Valuation
- Market cap
- —
- P/E
- —
Fundamentals
- Profit margin
- -0.5%
- ROE
- -211.6%
- Industry
- Drug Manufacturers—General
Market data
Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Profit margin, ROE · Fiscal year ended: 2025-12-31 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 78,238
- Previous report
- 80,533
- Avg daily volume
- 27,246
- Days to cover
- 2.9
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 6,550 | USD 3.10 | USD 20,305 | SEC filing ↗ |
| 2026-04-22 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 2,900 | USD 3.76 | USD 10,904 | SEC filing ↗ |
Form 4 evidence
2 transaction lines in the latest 365-day window; 2 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 6,550 | USD 3.10 | USD 20,305 | SEC filing ↗ |
| 2026-04-22 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 2,900 | USD 3.76 | USD 10,904 | SEC filing ↗ |
Show recent Form 4 evidence (2 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-06-17 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 6,550 | USD 3.10 | USD 20,305 | SEC filing ↗ |
| 2026-04-22 | Teleman Dan Benjamin | Purchase (P) | Ordinary Shares | 2,900 | USD 3.76 | USD 10,904 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | NSRX |
| CIK | 0002029039 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | NYSE |
Data coverage
| Local Form 4 history | 2 transaction lines from 2026-04-22 to 2026-06-17 2 P purchase lines · 0 S sale lines · 0 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.